Visit go.covermymeds.com/OptumRx to begin using this free service

## Overactive Bladder: Detrol®, Detrol® LA, Ditropan XL®, Myrbetriq®, Oxytrol®, Toviaz® & Vesicare® Prior Authorization Request Form (Page 1 of 2) DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY HAVE BARCODES.

This form may be faxed to 844-403-1029.

Member Name:	Provider Name:			equired)
Insurance ID#:	NPI#:	NPI#: Specialty:		
Date of Birth:	Office Phone:	Office Phone:		
Street Address:	Office Fax:			
City: State: ZIP:	Office Street Address	Office Street Address:		
Phone:	City:	State:	ZI	P:
Medication I	nformation (require	d)		
Medication Name:	Strength:	Dosage Form:		:
	Directions for Use:			
Clinical Int	ormation (required)			
Select the diagnosis below:	Officiation (required)			
☐ Overactive bladder				
☐ Other diagnosis:	ICD-10 Code:			
2. Has the patient demonstrated a failure of or intolerance to a majority (two or more in a class with at least two alternatives or one in a class with only one alternative) of the preferred formulary/preferred drug list alternatives for the given diagnosis [e.g., oxybutynin extended-release (ER), tolterodine, tolterodine ER, trospium, trospium ER, solifenacin, Gelnique]?				☐ Yes ☐ No
3. Does the patient have a documented contraindication to the listed formulary alternatives (e.g., oxybutynin ER, tolterodine, tolterodine ER, trospium, trospium ER, solifenacin, Gelnique)?				☐ Yes ☐ No
4. Has the patient had an adverse reaction to OR would be reasonably expected to have an adverse reaction to a majority (two or more in a class with at least two alternatives or one in a class with only one alternative) of the listed formulary agents used for the requested indication (e.g., oxybutynin ER, tolterodine, tolterodine ER, trospium, trospium ER, solifenacin, Gelnique)?				☐ Yes ☐ No
5. Does the patient have a clinical condition for which there condition based on published guidelines or clinical litera		gent to trea	it the	☐ Yes ☐ No
6. Is the drug being prescribed within the manufacturer's published dosing guidelines or does the dose fall within dosing guidelines found in accepted compendia or current literature (e.g., package insert, AHFS, Micromedex, current accepted guidelines, etc.)?				□ Yes □ No
Information on this form is accurate as of this date.				
Prescriber's Signature:		Da	ate:	

This document – and others if attached – contains information that is privileged, confidential and/or may contain protected health information (PHI). The provider named above is required by applicable law to safeguard PHI. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

Office use only: OveractiveBladder\_2019Dec

## Overactive Bladder: Detrol<sup>®</sup>, Detrol<sup>®</sup> LA, Ditropan XL<sup>®</sup>, Myrbetriq<sup>®</sup>, Oxytrol<sup>®</sup>, Toviaz<sup>®</sup> & Vesicare<sup>®</sup> Prior Authorization Request Form (Page 2 of 2)

this review?	ne physician feels is important to
uno review.	

Please note:

This request may be denied unless all required information is received.

For more information about the prior authorization process, please contact us at 855-811-2218. Monday – Friday: 8 a.m. to 1 a.m. Eastern, and Saturday: 9 a.m. to 6 p.m. Eastern